Evaluation for NCI Surgery Branch Clinical Research Protocols
Recruiting
7,000 enrolled
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Phase 1 Recruiting
60 enrolled
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
Phase 1 Recruiting
39 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
Phase 1 Recruiting
36 enrolled
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/2 Recruiting
58 enrolled
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Phase 1 Recruiting
30 enrolled
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Phase 1 Recruiting
30 enrolled
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
Phase 2 Recruiting
38 enrolled
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Phase 1 Recruiting
24 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Phase 1/2 Recruiting
86 enrolled
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Recruiting
1,800 enrolled
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Phase 1 Recruiting
116 enrolled
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase 1/2 Recruiting
60 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 Recruiting
332 enrolled
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Phase 2 Recruiting
70 enrolled